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BACKGROUND. Extracellular vesicles (EVs) are cell-derived membrane vesicles. EVs
contain several RNAs such as mRNA, microRNAs, and ncRNAs, but less is known of their
genomic DNA (gDNA) content. It is also unknown whether the DNA cargo is randomly
sorted or if it is systematically packed into specific EV subpopulations. The aim of this study
was to analyze whether different prostate cancer (PCa) cell-derived EV subpopulations
(apoptotic bodies, microvesicles, and exosomes) carry different gDNA fragments.
METHODS. EV subpopulations were isolated from three PCa cell lines (LNCaP, PC-3, and
RC92a/hTERT) and the plasma of PCa patients and healthy donors, and characterized by
transmission electron microscopy, nanoparticle tracking analysis and total protein content.
gDNA fragments of different genes were detected by real time quantitative PCR and
confirmed by DNA sequencing.
RESULTS. We report that the concentration of EVs was higher in the cancer patients than in
the healthy controls. EV subpopulations differed from each other in terms of total protein and
DNA content. Analysis of gDNA fragments of MLH1, PTEN, and TP53 genes from the PCa
cell-derived EV subpopulations showed that different EVs carried different gDNA content,
which could even harbor specific mutations. Altogether, these results suggest that both nucleic
acids and proteins are selectively and cell-dependently packed into the EV subtypes.
CONCLUSIONS. EVs derived from PCa cell lines and human plasma samples contain
double-stranded gDNA fragments which could be used to detect specific mutations, making
EVs potential biomarkers for cancer diagnostics and prognostics. Prostate 74:1379–1390, 2014.
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INTRODUCTION
Extracellular vesicles (EVs) are heterogeneous pop-
ulations of membrane vesicles released by cells into
their microenvironment and blood circulation. EVs are
important mediators of intercellular communication
and disease progression, and they are considered to
play a fundamental role in many physiological and
pathological processes [1,2]. The nomenclature and
classification of EVs are still undefined, and even the
purest vesicle samples can remain heterogeneous,
being only isolated as an EV subtype-enriched popula-
tion by the currently available purification techni-
ques [3]. Presently, a broad consensus classifies EVs
into three main classes based on the differences in their
size, formation mechanism, and content [1]. Apoptotic
bodies (ABs) are the largest EVs, with a size range of
1–4mm [4]. They are released by all cell types during
the late stages of apoptosis. It is widely known that
ABs contain nuclear material from the dying cells,
being able to participate in the horizontal transfer of
oncogenes [5]. Microparticles or microvesicles (MVs)
are plasma membrane-derived vesicles defined as 0.2–
1.0mm in size, which are formed by outward shedding
of the plasma membrane [2]. Exosomes (EXOs) are the
smallest membranous vesicles, between 40 and 100 nm
in diameter. They are first secreted into the endosome-
derived multivesicular bodies and then liberated by
the fusion of the multivesicular body with the plasma
membrane [1].
The oncogenic alteration of cancer cells is known to
influence both the number of secreted EVs and direct
the inclusion of tumor-related molecules into the EV
cargo [6,7]. The presence of cancer markers in EVs
combined with their release into body fluids, such
as blood, urine or semen, highlights their potential use
as non-invasive biomarkers [8]. Messenger RNAs
(mRNAs) of PCA3 and TMPRSS2-ERG genes have
previously been discovered in EXOs from urine of
both prostate cancer (PCa) patients [9,10] and mice
grafted with human PCa [11]. It has also been
demonstrated that prostasomes, EXOs derived from
the seminal fluid, contain chromosomal DNA [12]. In
addition, the transfer of the tumor suppressor PTEN
through EXOs conferring tumor-suppression activity
to acceptor cells has been recently proven [13]. The
enrichment of mRNAs and microRNAs in EVs sug-
gests that nucleic acids may be selectively packaged
into them [8]. However, it is still unclear if the cargo is
randomly packed in EVs, or whether it is sorted
among different EV subpopulations, making some EV
types more likely to carry certain material than others.
We investigated if the diverse EV subpopulations from
different sources contained gDNA fragments. To test
this hypothesis, we extracted gDNA from ABs, MVs,
and EXOs derived from different malignant PCa cell
lines and from plasma of both PCa patients and
healthy donors. We proved that the EV subpopula-
tions from the cell culture supernatants and plasma
contained different gDNA fragments, and in some
cases DNA harboring TP53 and PTENmutations.
MATERIALSANDMETHODS
Cell Lines
LNCaP and PC-3, commercial PCa metastatic cell
lines (from ATCC), and RC92a/hTERT, human telome-
rase reverse transcriptase (hTERT)-immortalized prima-
ry malignant tumor-derived human prostate epithelial
cell line (a kind gift of Dr. Rhim JS, University of the
Health Sciences, Bethesda, MD), were grown at 37°C
and 5% of CO2 atmosphere to 80% confluence. LNCaP
cells were grown in RPMI 1640 medium supplemented
with 10% fetal bovine serum (FBS). The FBS was
vesicle-depleted by an overnight ultracentrifugation at
110,000g, followed by filtration through 0.22mm filter
(Millipore). PC-3 cells were grown in DMEM/F12
medium supplemented with 10% FBS. RC92a/hTERT
cells were grown and maintained in a Keratinocyte
serum-free medium supplemented with bovine pitui-
tary extract and recombinant epidermal growth factor.
All media were supplemented with 2.5% of penicillin–
streptomycin. All reagents were purchased from Life
Technologies.
Plasma Samples
EDTA blood samples, taken from four PCa patients
and four healthy male donors, were collected at
Tampere University Hospital (Finland) after receiving
written consent (ethical permission number R03203).
Detailed information about the patients is presented in
Table I. Samples were stored at 4–8°C and processed
within 12 hr.
ExtracellularVesicles Isolation
EVs from plasma samples (2ml), and cell-conditioned
media (300ml) produced from 1.8–2 108 cells, were
isolated by differential ultracentrifugation. To remove
cellular debris, samples were centrifuged at 1,000g
for 10min. This was followed by a centrifugation at
1,200g for 30min to obtain the ABs. The supernatant
was centrifuged at 20,000g for 60min to obtain the
MVs. The remaining supernatant was filtered using a
0.22mm membrane filter and ultracentrifuged at
110,000g for 60min to obtain EXOs (Optima-LE
80K ultracentrifuge, 50.2 Ti rotor, and Beckman tubes
(Beckman Coulter)). All centrifugations were performed
1380 Lazaro-Iba~nez et al.
The Prostate
at 4°C. The final pellets were resuspended in 100ml of
Dulbecco’s phosphate buffered saline (1 DPBS) (Life
Technologies). A sample of the EV-free supernatant
collected after the ultracentrifugation was also treated
similarly and used as a negative control. Samples were
immediately used or stored at 80°C. EV number was
normalized per ml of cell culture media containing the
vesicles from million cells. From patient samples and
healthy donors, the number of the isolated EVs was
normalized per ml of plasma.
Transmission ElectronMicroscopy (TEM)
EVs samples (4ml) were individually added onto
glow discharged 150mesh formvar copper grids
(EMSTM) and incubated for 2min at 4°C. The grids
were washed, negatively stained with 2% aqueous
uranyl acetate, dried, and analyzed by TEM (FEI
Tecnai Spirit G2 and FEI Tecnai 12) at 80 kV. Images
were taken by digital camera (Soft Image System,
Morada and Gatan Orius SC 1000B CCD-camera).
NanoparticleTrackingAnalysis (NTA)
EV subpopulations were analyzed using a Nano-
particle Tracking Analyzer LM10 with red laser
(638 nm, 40mW, Nanosight Technology) and Merlin F-
033B ASG-camera (Allied Vision Technologies GmbH)
to provide data on size distribution and EV concentra-
tion. All the EV samples were diluted 1:50–1:100 in
DPBS before analysis. Three measurements were per-
formed for each sample in which the analysis settings
remained unaltered within experiments (camera level
14, auto-settings off, polydispersity high, and repro-
ducibility high). Data analysis was performed with
NTA 2.3 software (Nanosight). In all cases, the median
particle size, standard deviation, size distribution, and
particle concentration values were obtained.
ProteinQuantif|cation
EVs were analyzed for total protein contents using
the MicroBCA protein assay kit (Thermo Scientific).
Prior the protein extraction, EV samples were washed
three times with DPBS and incubated at 95°C for
10min. EVs preparations, usually diluted 1:10 to 1:50
in DPBS, were compared in triplicates against serially
diluted bovine serum albumin standard. After 2 hr of
incubation, the samples were analyzed in a microplate
reader Varioskan Flash (v.2.4.3) (Thermo Scientific),
using a 562 nm absorbance filter. The protein concen-
tration was determined by the standard curve and the
optical density value of the samples.
DNAIsolation and Pre-Amplif|cation
Prior to the DNA isolation, samples were treated
with 100mg/ml RNase A (Thermo Scientific) for 2min
at room temperature and 27KunitzU/ml DNase I
(Quiagen) for 30min at 37°C respectively in order to
remove possible nucleic acids contaminants. After
treatment, the enzymes were inactivated using Ribo-
Lock RNase Inhibitor (Fermentas) and heat inactiva-
tion. Total DNA was extracted from EVs and cells
using DNeasy blood and Tissue Kit (Qiagen) following
manufacturer’s recommendations. The extracted DNA
was pre-amplified using the GenomePlex Complete
WGA2 Kit (Sigma-Aldrich), according to manufac-
turer’s instructions, and then diluted to 10 ng/ml
working solution. The spectrum, double-stranded
DNA concentration, and quality of the extracted DNA
were estimated in all the samples using SPECTROstar
Nano (BMG Labtech) and 2100 Bioanalyzer (Agilent).
PCRAnalysis and Sequencing
PCR analysis was performed with preamplified
gDNA products from ABs, MVs, and EXOs from both
PCa cell lines and plasma samples, using the specific
designed primers (Table II and Supplementary
Fig. S3). Each experiment was repeated a minimum of
three times. The PCR reaction mixture contained 2mM
Mg2þ, 100mM dNTP mix, 10mM of each primer, 5U/
ml of Paq 5000 DNA polymerase (Aguilent Technolo-
gies), 10 ng of gDNA and DEPC H2O up to 25ml. PCR
was performed in a T100 Thermal cycler (BioRad) and
TABLEI. Characteristics of the Prostate Cancer Patients
Patient
number Gender
Clinical stage
PSA
(ng/ml)
Test leading to
diagnosis
Gleason
scorecT cN cM
6 Male T3 NX M0 18 PSA 7
7 Male T1c NX M0 26.6 PSA 7
8 Male T1c N0 M0 7 PSA 6
9 Male T3 NX MX 7.8 Symptomatic 8
Patient number, gender, clinical stage, PSA (ng/ml), test leading to diagnosis, and Gleason score are showed.
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the thermal cycles were used as follows: 1 cycle of
2min at 95°C, 34 cycles for 20 sec at 95°C, 20 sec at
60°C and 30 sec at 72°C, and 5min at 72°C. The
resulting PCR-products were validated by electropho-
resis in 1% agarose gels. The bands were extracted and
purified from the gel (Gel extraction kit and QIAqick
PCR purification kit, Quiagen). Subsequently, a se-
quencing reaction was performed using BigDye Termi-
nator (v.3.1) Cycle Sequencing Kit (Applied
Biosystems), and run in an ABI 3730 DNA analyzer
automated sequencer (Applied Biosystems).
Real-TimeQuantitative PCR (qPCR)
Relative quantification of parts ofMLH1, PTEN, and
TP53 genes for the cell-derived EVs was determined
by qPCR. qPCR assays were performed using a Light-
cycler 480 (Roche Diagnostics). All the samples, external
standards, and non-template controls were run in
triplicate. For each 20ml PCR reaction, 10ml of Fast
SYBR Green Master Mix (Applied Biosystems), 300nM
of each primer, and 50ng of DNA were used. The
thermal cycle parameters were as follows: enzyme
activation at 95°C for 20 sec, 40 cycles of denaturation
at 95°C for 1 sec, and annealing and extension at 60°C
for 20 sec. DNA detection was performed using specific
primer pairs (Sigma-Aldrich) which were designed
using Primer 3 and nucleotide Blast (Blastn) tools (see
Table II). The melting curves and Ct values were
analyzed with Lightcycler 480 software (v.1.5), and
the resulting values were reviewed manually for a
correct analysis. Normalized relative ratio values
for MLH1, PTEN, and TP53 gDNA fragments were
calculated by comparison with the relative amount
obtained for Glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) [14].
Statistical Analysis
Statistical analyses were performed using statistical
software R-project (v.3.0.2). In all experiments,
Student’s t-test assessed by a Shapiro–Wilk test or
nonparametric Wilcoxon signed ranked test were
used. The results were always considered statistically
significant (two sides) in the following scale: P< 0.05;
P< 0.01; P< 0.001. Results are represented as
mean standard error (SE).
RESULTS
Morphological Characterization and Size
Distributionof ABs,MVs, and EXOs
Different EV subpopulations generated by LNCaP,
PC-3, and RC92a/hTERT cell cultures, as well as
from human plasma samples, were isolated by differ-
ential centrifugations, visualized by TEM, and size
measured by NTA (Fig. 1). TEM and NTA are
complementary techniques. TEM offers a precise
observation of the size morphology and heterogeneity
of individual vesicles, while NTA is more appropriate
for observation of EV size distribution and concentra-
tion. TEM data revealed that we were able to morpho-
logically separate three different enriched vesicle
populations: ABs, pelleted at 1,200g, were within
the previously reported size rage of 1–4mm [4]
(Fig. 1A. a1–c1). MVs, isolated at 20,000g, were
within a diameter range of 0.2–1mm. They were more
heterogeneous in size and morphology with a predom-
inant oval and spherical shape (Fig. 1A. a2–c2). EXOs
obtained after 0.22mm filtration and subsequent
ultracentrifugation at 110,000g were more homoge-
neous in shape, and within a size range of 40–100 nm
(Fig. 1A. a3–c3). TEM results (Fig. 1A) verified that
we were able to isolate highly purified populations
of ABs, MVs, and EXOs free of cellular debris and
protein aggregates. The EV subpopulations from the
different cell lines and plasma samples had a similar
morphology (Supplementary Fig. S1), with intact
structures, confirming that different cell sources pro-
duced similar EV populations with comparable sizes,
using the same isolation protocol. The mean size of
MVs and EXOs for LNCaP, PC-3, and RC92a/hTERT,
from NTA measurements, together with the size
TABLEII. PCRPrimer Sequences
Primer name Gene Sequence 50–30 Tm nt # Amplicon size (bp)
hGAPDH_FW GAPDH TCCTCCACCTTTGACGCTG 60 19 101
hGAPDH_Rw ACCACCCTGTTGCTGTAGCC 62 20
hMLH1_gI7-E8_FW MLH1 ttatcagCAAGGAGAGACAGTAGC 59 24 108
hMLH1_gE8-I9_Rv cgacatacCGACTAACAGCATTT 60 23
hPTEN_gE1_FW PTEN GCCAAGTCCAGAGCCATT 60 18 225
hPTEN_gI1_Rv aagagagtgacagaaaggtaaagagg 60 26
hTP53_gE3-I3_FW TP53 CTGgtaaggacaagggttgg 59 20 316
hTP53_gE4_Rv CTGGGAAGGGACAGAAGATG 60 20
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distribution histograms are shown in the Figure 1B. In
addition, the mean size of MVs and EXOs derived
from the PCa patients and healthy donors plasma
samples are also provided (Supplementary Table SI) in
order to prove that in both cases, the isolated MVs and
EXOs from plasma were also in the same size distribu-
tion range described for each EV subtype. In the NTA
measurements, the partial overlap between the MV
and EXO populations may be due to the intra-sample
variability, the presence of other particles from the
plasma (lipoprotein and immune complexes) and also
the vesicle aggregation (Fig. 4C). ABs could not be
measured because their size range was out of the
detection limits of the NTA technique.
EVsAreMoreAbundant in the Plasmaof Cancer
PatientsThan inHealthyDonors
In order to measure the EV concentration, both cell-
derived and plasma-derived EV samples were ana-
lyzed by NTA (Fig. 2). Although the cancer cells used
in this study were morphologically very heteroge-
neous, their MVs and EXOs had comparable sizes and
concentrations. Particle concentration was normalized
per million cells to be comparable between the differ-
ent cell lines. The concentration of MVs (n¼ 16) and
EXOs (n¼ 16) in each cell line was quite similar, within
the range of 1.36–2.52 108 particles/ml per million
cells for MVs, and 0.56–1.93 108 particles/ml per
million cells for EXOs (Figs. 2A and B).
Although the MVs and EXOs concentrations from
the three cell lines seemed to differ from one another
(Fig. 2A), the results did not reach statistical signifi-
cance. Regarding the plasma samples, the concentra-
tion of MVs and EXOs was higher in cancer patients
than in healthy donors (Supplementary Fig. S4).
However, the results did not reach statistical signifi-
cance, and it was only observed when the analysis
were done with the total EV population when the
EVs derived from the PCa patients and healthy
donors were significantly different from each other
(P¼ 0.018); the mean EV concentration being higher
for cancer patients (Figs. 2B and C). The concentration
of ABs could not be measured due to limitations in the
Fig. 1. Characterization of cell-derived extracellular vesicle subpopulations.A: Representative transmission electronmicroscopy images
of different EV populations: apoptotic bodies (a1^c1), microvesicles (a2^c2) and exosomes (a3^c3) released from LNCaP, PC-3, RC92a/
hTERT cell lines.The scale bar is included in each picture.B: Size distribution graphics ofmicrovesicles (MVs) and exosomes (EXOs) derived
fromLNCaP,PC-3, andRC92a/hTERT cellswere determinedbyNTAusingNanosight software.Themeanparticle size for eachpopulation is
represented.
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detection limit of the NTA technique. However, on the
basis of the TEM images, there were much less ABs
compared with MVs and EXOs in all samples.
EVSubpopulationsHaveDifferent
Total Protein Contents
To determine the total protein contents of the EV
subpopulations, the microBCA assay was used
(Fig. 3). Protein results were normalized per million
cells to be comparable between different cell lines. We
hypothesized that depending on the origin and vesicle
type, EVs would have different protein contents. As
shown in Figure 3A, the total protein contents between
MVs and EXOs (n¼ 12) from the three cell lines were
different, being almost double for MVs (6mg protein/
106 cells) compared with EXOs (3.2mg protein/106
cells). Looking at the EV subpopulations by cell line,
significant differences were observed between PC-3
and RC92a/hTERT EXOs (P¼ 0.001), LNCaP and
PC-3 EXOs (P¼ 0.034), as well as between LNCaP
and PC-3 MVs (P¼ 3.50E04), LNCaP and RC92a/
hTERT MVs (P¼ 1.40E05), and PC-3 and RC92a/
hTERT MVs (P¼ 0.0036; Fig. 3A), LNCaP MVs being
the EVs with the highest protein content. In addition,
the protein contents of LNCaP MVs (n¼ 5) and EXOs
(n¼ 4) also significantly differed from each other,
10mg protein/106 cells and 3mg protein/106 cells,
respectively (P¼ 0.035; Fig. 3B). The total protein
contents of EVs from the PCa patients and healthy
Fig. 2. Particle concentration of microvesicles and exosomes from prostate cell lines and plasma samples.A: Barplots representing the
nanoparticle tracking analysis results depicting theparticle concentration ofmicrovesicles (MVs) and exosomes (EXOs) permillion cells per
cell line. LNCaP MVs (n¼ 8); PC-3 MVs (n¼ 4); RC92a/hTERTMVs (n¼ 4); LNCaP EXOs (n¼ 6); PC-3 EXOs (n¼ 4); RC92a/hTERT EXOs
(n¼ 5); error bars represent SE; P valueswere determinedby unpairedWilcoxon signedranked test (upper bar plots) andpairedWilcoxon
signed ranked test (lower bar plots).B: Nanoparticle tracking analysis of MVs and EXOs derived from cell lines and plasma samples.The
concentration (particles/ml) is normalizedpermillion cells for EVs derived fromprostate cell lines.C:Dotplot showing the total EVparticle
concentration permilliliter of plasma for patients (n¼ 8) andhealthy donors (n¼ 8); error bars represent SE; P< 0.05, was determinedby
unpairedStudent’st-test.
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donors were also analyzed. Although protein results
paralleled the vesicle concentration results shown
in Figure 2B, no significant differences were seen in
the MVs and EXOs or as a total EV population
between PCa patients and donors (Fig. 3C and
Supplementary Fig. S5). To determine if there was a
correlation between the particle concentration and
the protein content per EV subtypes, linear regres-
sion models were developed. Samples were grouped
on the basis of cellular origin. Plotting the correlation
of particles per microgram of protein demonstrated a
very high correlation of particles to protein in LNCaP
(R2¼ 0.9) and RC92a/hTERT-derived EVs (R2¼ 0.6;
Fig. 3C), showing in both cases a higher ratio of
particles to protein in MVs than in EXOs. However,
for PC-3-derived EVs there was no correspondence
(R2¼ 0.1), which showed that the correlation be-
tween the EV concentration and the total protein
content was totally dependent on the cellular source
of the EVs.
EVSubpopulations Contain Fragments of
Double-StrandedgDNA
To avoid external DNA/RNA contamination in the
analysis of the intravesicular content, the EV samples
Fig. 3. Total protein contents of EV subpopulations.A: Bar plots representing the total protein contents permillion cells ofmicrovesicles
(MVs) (n¼11) and exosomes (EXOs) (n¼12) isolated from LNCaP, PC-3, and RC92a/hTERT prostate cancer cells. Error bars represent SE.
P values determined by pairedWilcoxon signed ranked test.Comparison of the total protein content of EXOs and MVs between cell lines.
LNCaP MVs (n¼ 5); PC-3 MVs (n¼ 3); RC92a/hTERT MVs (n¼ 3); LNCaP EXOs (n¼ 3); PC-3 EXOs (n¼ 4); RC92a/hTERT EXOs (n¼ 5);
error bars represent SE; P< 0.05, P< 0.01, P< 0.001byunpaired Student’s t-test.B: Comparison of the totalprotein contentbetween
MVsandEXOs forLNCaP,PC-3,andRC92a/hTERTcells.ErrorbarsrepresentSE;P valuesweredeterminedbypairedWilcoxonsignedranked
test.C:Dotplot showing the total EVproteincontent frompatients (n¼ 8) andhealthydonors (n¼ 8).Errorbarsrepresent SE;P values de-
termined by unpaired Student’s t-test.D: Linear regressions of the correlation between the EV concentration and total protein content
permillioncells formicrovesicles (MVs) andexosomes (EXOs) isolated fromprostate cancercell lines.LNCaPMVsversusEXOs (R2¼ 0.905);
PC-3MVsversusEXOs(R2¼ 0.113); and,RC92a/hTERTMVsversusEXOs(R2¼ 0.623).
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were first incubated with DNase I and then with
RNAse A to exclude RNA contamination, as described
in Materials and Methods Section. To ensure that
the DNA amplified was gDNA, the primer sequences
were specifically designed spanning intronic–
exonic sequences (Table II), and the used DNA
pre-amplification kit was specific for gDNA. We
speculated that the different EV subpopulations
could also contain mutated DNA fragments depen-
dent of the cellular origin of the EVs. For this
analysis, a 108 bp fragment of MLH1 encoding intron
7 to intron 8, 225 bp fragment of PTEN spanning
from exon 1 to intron 1 as well as a 316 bp fragment
of TP53 encoding exon-intron 3 to exon 4 were
amplified (Fig. 4 and Supplementary Fig. S3). The
relative ratio of MLH1, PTEN, and TP53 fragments in
EV subpopulations was assessed by qPCR, using the
housekeeping GAPDH as a reference (Fig. 1A). The
presence of MLH1 fragments was confirmed in all
the cell-derived EV subpopulations, with the pre-
dicted product size of 108 bp, except for RC92a/
hTERT EXOs, where the gene fragment was absent
(Figs. 4A and B). A MLH1 mutation (I219V) has been
reported in the codon 655 (A>G) for LNCaP cells,
but we could not confirm this mutation in the
LNCaP-derived EVs (Fig. 4C). On the other hand,
Fig. 4. Presence ofmutatedDNAfragments inEVsubpopulations.A:Relativeratio ofMLH1,PTEN, andTP53 genomicDNA(gDNA) frag-
ments assessed by qPCR from subpopulations of EVs derived from LNCaP, PC-3, and RC92a/hTERT cells, using GAPDH as a reference gene.
TheGAPDH genewas used as reference due to its constant presence in all the vesicle types (Supplementary Fig. S2). Asterisk () represents
that the gene of interestwas notdetectablebyqPCRornotpresent in the samples analyzed.Columns are the average of three experiments,
each onemeasuredin triplicates.Errorbars represent SE.Apoptotic bodies: dark gray;microvesicles: gray; exosomes: lightgray.B: Agarose
gel electrophoresis ofMLH1, PTEN, and TP53 gDNA fragments extracted of EVs derived from LNCaP,PC-3, and RC92a/hTERT cells (n¼ 3).
Ladder (L), apoptotic bodies (ABs), microvesicles (MVs), exosomes (EXOs), supernatant from the last ultracentrifugation (SP), positive cell
control (Cþ) andnegative control (C).C: ElectropherogramsdisplayingPTEN andTP53mutations inABs andEXOs.PartofgenomicDNA
sequences ofMLH1, PTEN, and TP53 genes from LNCaP-derived vesicles, with noMLH1mutation (left), PTENmutation in codon 6 (Frame-
shiftmutations,delAA)(center) andTP53mutationincodon215(CCCtoCGC)(right).Thearrows show thepositionof themutations.
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PTEN fragments were detected in the LNCaP ABs and
EXOs with the predicted product size of 225 bp
(Fig. 4A,B). Sequencing analysis of these EV-derived
DNA fragments showed a frame-shift mutation in the
codon 6 (delAA) (K6fs4), previously described in
LNCaP cells [15,16]. Further, we assessed the presence
of TP53 in LNCaPABs with a 316 bp product (Fig. 4A,
B), also harboring a previously described polymor-
phism (P72R) for LNCaP cells [17], confirming the
previous observations that ABs can carry and transfer
oncogenic sequences [5]. For PTEN and TP53, these
mutations have been described to be absent in PC-3
cells [17], have not previously been studied in RC92a/
hTERT cells, and were not identified in this study
either. Finally, we assessed as a proof of concept
whether the plasma EVs contained gDNA fragments.
Although gDNAwas present in the patient EVs, these
specific mutations were not detectable in the patient
cohort (Fig. 5).
DISCUSSION
EVs are considered to play a key role in cell-to-cell
communication since they may transfer the genetic
cargo of their parental cells, and thus modulate the
biological functions of their recipient cells [18,19]. It is
known that EVs contain proteins, lipids, mRNA and
microRNA fragments [20,21] but the presence of DNA
has not been systematically reported so far. Mitochon-
drial DNA was found in astrocyte- and glioblastoma-
derived EXOs [22], and single-stranded DNA and
transposable elements were described in glioblastoma-
derived MVs [23]. In the present study, we show that
the PCa EVs contain double-stranded gDNA frag-
ments in all the different EV subpopulations: ABs,
MVs, and EXOs. Just recently, the presence of gDNA
was first reported in the EXOs of patients with
pancreatic cancer [24] which our findings accordingly
complement.
The presence of a part of both TP53 and PTEN
genes in the EV subpopulations was investigated as
they are the only genes significantly mutated in both
localized and castration-resistant PCa tumors, with a
broad role in cancer initiation, progression and treat-
ment resistance [25]. On the other hand, MLH1 germ-
line mutations were researched since they are very
rare in prostate tumors. In this preliminary study, we
could detect different gDNA cargos in diverse EV
subpopulations, which indicate that the molecular
content of the EVs is dependent on both the cellular
source and the specific vesicle subtype. Further, we
also demonstrate that the EV-derived DNA has the
same mutations in TP53 and PTEN genes as in their
parental tumor cells. The concept of EV subpopulation
and cell type-dependent packing of molecular cargo is
further supported by our finding of differential total
protein content within the EV subtypes, despite the
similar concentrations of the PCa cell-derived MVs
and EXOs.
Moreover, we also provide evidence as a proof of
concept that human plasma-derived EVs also carry
double-stranded gDNA fragments, and that plasma-
derived EVs are more abundant in PCa patients than
in healthy donors, as has been previously reported in
other cancer types [26]. However, the previously
described mutations for the LNCaP-derived EVs were
not detected from the plasma EV populations. The
inability to detect specific mutations in patients’
samples could be due to the heterogeneous origin of
EVs in the blood circulation, since EVs are also
released from other non-cancerous cells. Alternatively,
it could reflect that these specific mutations were
absent in this patient cohort. Further studies are
required to develop techniques to selectively enrich
and isolate tumor EV subpopulations from the total
EV pool in plasma.
Lately, the EV-mediated education of hematopoietic
cells within the bone marrow has been suggested to
be a fundamental step in the formation of pre-
metastatic niches [27]. We propose that by the secre-
tion of EVs, part of the gDNA content of the cell can
vesicle-specifically be sorted and travel around the
body as a EV-protected circulating DNA, which
contributes to both pre-metastatic niche formation
and tumor metastasis. As the EV cargo also likely
represents the dynamic molecular changes in the
tumor and its progression [26], EVs make a promising
candidate for diagnostic biomarkers. As DNA is
intrinsically more stable than RNA, the analysis of
genomic mutations may also be a more robust and
sensitive marker of dynamic changes. We consider
that the horizontal transfer and uptake of DNA
mediated by ABs, MVs, and EXOs could be one
possible mechanism for the generation of genetic
instability and diversity in cancer. Altogether, these
preliminary results warrant further research to use
tumor EVs and their gDNA content as an additional
biomarkers for diagnosis, prognosis and management
of PCa.
CONCLUSIONS
We have reported that different EV subpopulations
derived from PCa cell lines and plasma samples
contain different double-stranded genomic DNA frag-
ments which, depending on the cell source, can also
be mutated. These results may offer an explanation
for the horizontal transfer of oncogenes between
cancer and normal cells via EV-mediated transfer of
gDNA. Because tumor cells can release EVs into the
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blood stream, they could provide a stable source of
genetic information for cancer diagnosis, prognosis
and treatment. However, identification of more PCa-
specific nucleic acid biomarkers in EV subpopulations
as well as their correlation to clinical parameters are
needed before EVs can be fully utilized in tumor
diagnostics.
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